Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study
1997

Epirubicin and Estramustine for Prostate Cancer

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): EH Hernes, SD Fossb, S Vaage, P Ogreid, A Heilo, E Paus

Primary Institution: The Norwegian Radium Hospital

Hypothesis

The combination of epirubicin and estramustine phosphate is effective in treating hormone-resistant prostate cancer.

Conclusion

The combination of epirubicin and estramustine phosphate is tolerable and appears effective in achieving significant PSA reduction in patients with hormone-resistant prostate cancer.

Supporting Evidence

  • 54% of patients showed a biochemical response with a 50% reduction in PSA after treatment.
  • Patients experienced subjective improvements in pain and performance status.
  • Grade 3/4 leucopenia occurred in eight patients, indicating some level of toxicity.

Takeaway

Doctors tested two medicines together to help men with a tough kind of prostate cancer, and many of them had lower PSA levels, which is a good sign.

Methodology

This was a multicenter phase II study involving 24 patients who received a combination of epirubicin and estramustine phosphate, with outcomes measured by changes in serum PSA levels.

Potential Biases

Selection bias may have occurred as patients were chosen based on specific performance status and health conditions.

Limitations

The study had a small sample size and was limited to patients with specific eligibility criteria, which may not represent the broader population of patients with hormone-resistant prostate cancer.

Participant Demographics

Patients had hormone-resistant prostate cancer, with a performance status of 0 or 1 in 21 out of 24 patients.

Statistical Information

P-Value

< 0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication